Christopher Ryan Sullivan sold $1.5M of AVTX
Chief Financial Officer at Avalo Therapeutics, Inc.. 72,725 shares at an average of $19.94, traded Aug 17, 2026, filed Aug 19, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.5M at market
- +20Share of holdings soldSold 89% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001810417-26-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | MOption exercise Common Stock10b5-1 | +37,945 | $9.88 | $375k | 78,718 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Common Stock10b5-1 | +2,876 | $9.88 | $28k | 81,594 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock10b5-1 | -37,945 | $19.85 | $753k | 43,649 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock10b5-1 | -3,749 | $19.94 | $75k | 39,900 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Common Stock10b5-1 | +31,031 | $9.88 | $307k | 70,931 | Aug 19, 2026 |
| Aug 18, 2026 | SOpen-market sale Common Stock10b5-1 | -31,031 | $20.05 | $622k | 39,900 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,945 | $0.00 | $0 | 130,149 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,876 | $0.00 | $0 | 127,273 | Aug 19, 2026 |
| Aug 18, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -31,031 | $0.00 | $0 | 96,242 | Aug 19, 2026 |
Related signals
Other insiders at Avalo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $202k 12,394 shares | -24% | |
| 12Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $179k 10,185 shares | -20% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 37Weak | Avalo Therapeutics, Inc. | Jennifer Riley Chief Strategy Officer | $52k 2,655 shares | -7% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $93k 4,654 shares | -8% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $26k 1,450 shares | -3% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $11k 679 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.